fashion -WSS

fashion

author：explore 2025-09-30 17:46:14 - browse：12

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Pregnancy discrimination could be enabled by AI

WSS

Unique patient identifier: Experts argue the benefits, pitfalls

A protest over insulin prices is seen as a fight for life

AI models in health care face new federal disclosure requirements

The woman behind the Dana Farber

In diabetes hearing, Sanders takes on a new foe: food makers

SCOTUS to consider access to abortion pill mifepristone

focus

fashion

hotspot

How one medical school became remarkably diverse

SCOTUS to consider access to abortion pill mifepristone

Psychedelics group wrestles with new pharma identity

Texas Medical Board asked to define abortion emergency exception

Peter Hotez and the public health issue of online harassment

AstraZeneca stays mum on Medicare drug pricing negotiations

As demand for Covid shots wanes, Moderna seeks its next success

Patients' immediate access to test results puts radiologists in a bind

Anesthesiologist group: stop taking Ozempic before surgery

Unique patient identifier: Experts argue the benefits, pitfalls

entertainment

Devoted Health’s losses in Medicare Advantage persist

Readout LOUD: Venture capital, Gilead, and more M&A

The woman behind the Dana Farber

Why Novartis is going to walk from its acquisition of MorphoSys

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

FDA approves world's first CRISPR

focus

hotspot

focus

explore